- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06093815
생체 자극 제품 주입 후 조직 반응을 평가하기 위한 전향적 연구
다양한 생체 자극 제품을 주사한 후 조직 반응을 확인하고 평가하기 위한 전향적, 단일 현장, 통제된 비교 연구
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study.
Safety endpoint: incidence of adverse events.
연구 개요
상세 설명
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol.
Assessments under this protocol will include ultrasound of in vivo tissue.
Safety endpoint: incidence of adverse events.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Marbella, 스페인
- Ocean Clinic - Av. Ramon y Cajal 7, 29601
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy male & females; 22 to 65 years of age.
- Voluntary participation
- Ability to comprehend and provide informed consent.
- Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period.
- Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period.
- Participants agree NOT to undergo any surgical treatments in the treatment area during the study period.
- Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion Criteria:
- Any previous surgery in the abdominal area.
- Any previous treatment in the abdominal area.
- Planning to receive treatment of any kind in the abdominal area.
- Acute inflammatory process and/or infection at the injection site.
- Treatment of skin area with dermatosis.
- Eczema, exanthema or open wounds.
- Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study.
- Any contraindication to treatment with biostimulatory products based on the product's IFU.
- Previous pregnancy or intending to become pregnant during study participation.
- Known hypersensitivity to biostimulatory products or any of their formulation ingredients.
- Allergic reaction to topical and local anesthetics.
- Currently using anticoagulant therapy.
- Haemophilia / bleeding disorder.
- Chemotherapy, radiotherapy or high doses of corticosteroids.
- Systemic infection (e.g., hepatitis).
- Uncontrolled diabetes mellitus.
- Any medical condition that may put the participant at increased risk with exposure to biostimulatory products.
- Any medication that might modulate the immune response.
- Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant.
- Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating.
- Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study.
- Injection of local anesthesia into the flap during abdominoplasty surgery.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 1
Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse(+) undiluted, Radiesse diluted 1:1, Radiesse diluted 1:2, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
실험적: Arm 2 - Radiesse Classic (1:1 Dilution)
Five participants in Arm 2 will receive Radiesse Classic diluted 1:1 with sterile saline (CaHA-CMC 1:1) and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
실험적: Arm 2 - Sculptra
Five participants in Arm 2 will receive Sculptra diluted with 5 mL of sterile saline and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Arm 1 - Ultrasound Analyses - Skin Thickness (mm)
기간: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Elastosis
기간: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Microvascular Formation
기간: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at the injection site and reported according to the study-defined category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Skin Thickness (mm)
기간: 6 months prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Elastosis
기간: 6 months prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Microvascular Formation
기간: 6 months prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at injection site and reported according to the study-defined category/grade. |
6 months prior to surgery timepoint(s)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety Assessment
기간: through study completion, an average of 6 months
|
Any patient- or investigator-observed adverse event |
through study completion, an average of 6 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Ann P Marx, MD, Merz North America, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M900311010
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
individual data will be summarized for analyses
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .